Skip Navigation



Annals of Oncology Advance Access published online on May 19, 2007
Annals of Oncology, doi:10.1093/annonc/mdm138
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
18/8/1395    most recent
mdm138v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kelly, L
Right arrow Articles by Stone, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kelly, L
Right arrow Articles by Stone, P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 European Society for Medical Oncology

The B12/CRP index as a simple prognostic indicator in patients with advanced cancer: a confirmatory study

L Kelly1,*, S White2 and PC Stone2

1 Palliative Medicine, Surrey and Sussex Healthcare NHS Trust
2 Division of Mental Health, St George's University of London, UK

* Correspondence to: Dr L. Kelly, Surrey and Sussex Healthcare NHS Trust, Canada Avenue, Redhill, Surrey RH1 5RH, UK. Tel: +44-1737-768511 ext. 2660; Fax: +44-1737-231949; E-mail: laura.kelly{at}sash.nhs.uk

Background: The vitamin B12/C-reactive protein Index (BCI) has been proposed as a prognostic indicator in patients with advanced cancer. The purpose of this study was to confirm the utility of the BCI in palliative care patients.

Patients and methods: Patients with advanced cancer provided a blood specimen for analysis. Demographic and disease-related variables were recorded. Patients were followed up for at least 90 days or until death.

Results: Patients (n = 329) were divided into three groups according to their BCI score. Patients in group 3 (BCI >40 000; median survival 29 days) had a significantly (P < 0.01) worse survival than patients in group 2 (BCI 10 001–40 000; median survival 43 days) and patients in group 1 (BCI ≤10 000; median survival 71 days). However, patients in group 1 did not have a significantly better prognosis than those in group 2 (P = 0.091). The point estimates for 90-day mortality for each of the three risk groups were different from the figures previously reported during the development phase of the BCI (group 1, 58.9% versus 47.2%; group 2, 64.0 versus 72.5%; group 3, 78.9% versus 90.6%).

Conclusions: An elevated BCI (>40 000) predicts poor survival in patients with advanced cancer.

C-reactive protein, neoplasms, palliative care, prognosis, survival, vitamin B12

Received for publication December 15, 2006. Revision received March 16, 2007. Accepted for publication March 23, 2007.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Palliat MedHome page
P Stone, L Kelly, R Head, and S White
Development and validation of a prognostic scale for use in patients with advanced cancer
Palliative Medicine, September 1, 2008; 22(6): 711 - 717.
[Abstract] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.